Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295069 | 0.75 | — | — | |
| Hydrogen Sulfide SCHEMBL28275355 | 0.73 | — | — | |
| SCHEMBL28914873 | 0.73 | DAO (0.32) | DAOHDAC8HDAC6 | |
| SCHEMBL8526058 | 0.71 | DAO (0.30) | DAOHDAC8HDAC6 | |
| SCHEMBL28863955 | 0.71 | — | — | |
| SCHEMBL4409393 | 0.70 | — | — | |
| SCHEMBL10366551 | 0.70 | DAO (0.37) | DAOHDAC8HDAC6 | |
| Thiourea SCHEMBL28276604 | 0.70 | CYP1A2 (0.35) | DAOHDAC8HDAC6 | |
| SCHEMBL1345605 | 0.69 | DAO (0.35) | DAOHDAC8HDAC6 | |
| SCHEMBL6547242 | 0.68 | DAO (0.33) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | claimed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | claimed |
| EP-2172468-A1 | Benzimidazolone compounds | EURO-CELTIQUE S.A. (LU) | 2010-04-07 | — | — | EP | claimed |
| EP-1975164-B1 | Octahydrobenzimidazolone compounds as analgetics | EURO CELTIQUE SA (LU) | 2010-01-27 | — | — | EP | claimed |
| US-20090253727-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2009-10-08 | — | — | US | claimed |
| US-7563809-B2 | Nociceptin analogs | PURDUE PHARMA, L.P. (US) | 2009-07-21 | — | — | US | claimed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | claimed |
| EP-2050450-A1 | 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2009-04-22 | — | — | EP | claimed |
| EP-1997818-A2 | Quinolinone derivatives and their use to treat pain | EURO-CELTIQUE S.A. (LU) | 2008-12-03 | — | — | EP | claimed |
| EP-1379246-B1 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2008-10-08 | — | — | EP | claimed |
| EP-1379252-A2 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | claimed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | claimed |
| US-20030027834-A1 | Spiropyrazole compounds | PURDUE PHARMA L.P. | 2003-02-06 | — | — | US | claimed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| US-20030013874-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2003-01-16 | — | — | US | claimed |
| US-20030008886-A1 | Benzimidazolone compounds | PURDUE PHARMA L.P. | 2003-01-09 | — | — | US | claimed |
| WO-2002085355-A1 | SPIROPYRAZOLE COMPOUNDS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085357-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085291-A2 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008886-A1 | Benzimidazolone compounds | MRPS28, B2M, CCNI | DAO 4044/4885HDAC8 987/4885HDAC6 460/4885 |
| US-20030013874-A1 | Nociceptin analogs | OPRL1, OPRK1, NPBWR1 | DAO 2486/4885HDAC8 3545/4885HDAC6 1671/4885 |
| US-20090253727-A1 | NOCICEPTIN ANALOGS | OPRL1, NPBWR1, OPRK1 | DAO 2721/4885HDAC8 3408/4885HDAC6 1423/4885 |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | DAO 2300/4885HDAC8 3353/4885HDAC6 1726/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | DAO 2300/4885HDAC8 3353/4885HDAC6 1726/4885 |
| US-20030027834-A1 | Spiropyrazole compounds | REN, ADRA1B, NR3C2 | DAO 3246/4885HDAC8 474/4885HDAC6 140/4885 |
| US-20030069249-A1 | Nociceptin analogs | OPRL1, NPY1R, OPRK1 | DAO 2346/4885HDAC8 3671/4885HDAC6 1972/4885 |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | DAO 4067/4885HDAC8 771/4885HDAC6 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.